



DOCKET NO.: ISIS60040-100 (RTS-0303)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Bennett and Dobie**

Serial No.: **10/020,478**

Group Art Unit: **1635**

Filed: **December 13, 2001**

Examiner: **Jane J Zara**

Title: **Antisense Modulation Of B-Cell Associated Protein Expression**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

DECLARATION UNDER 37 CFR §1.132

I, Dr. Susan Freier, a citizen of the United States, residing at 2946 Renault Street, San Diego, CA 92122, state and declare as follows:

1. I hold a B.A. in Mathematics (1972) from Carleton College, Northfield, Minnesota and a Ph.D. in Chemistry (1976) from the University of California, Berkeley, California.

2. I have been employed by Isis Pharmaceuticals, Inc. ("Isis"), for about fourteen years. Isis, the assignee of the above-identified patent application, specializes in oligonucleotide technology and uses the latest in bioinformatics programs to identify sites on selected genes for oligonucleotide screening. I am presently the Executive Director of antisense lead identification at Isis and am responsible for several projects. I lead a project utilizing antisense oligonucleotides for functional genomics of novel targets, including the use of computational genomics to characterize target RNAs and their variants, rapid throughput screening to identify active antisense oligonucleotides for novel targets, and Q-RT-PCR and microarrays for expression analysis. I also lead a project for determining microRNA function in mammals, including the use of computational identification of microRNAs and microRNA targets and the use of functional genomics to characterize microRNA biology and identify therapeutic applications of modulation

DOCKET NO.: ISIS0040-100 (RTS-0303)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bennett and Doble

Serial No.: 10/020,478

Group Art Unit: 1635

Filed: December 13, 2001

Examiner: Jane J Zara

Title: Antisense Modulation Of B-Cell Associated Protein Expression

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

*considered
12-21-04
JZ*

DECLARATION UNDER 37 CFR §1.132

1. Dr. Susan Freier, a citizen of the United States, residing at 2946 Renault Street, San Diego, CA 92122, state and declare as follows:

1. I hold a B.A. in Mathematics (1972) from Carleton College, Northfield, Minnesota and a Ph.D. in Chemistry (1976) from the University of California, Berkeley, California.

2. I have been employed by Isis Pharmaceuticals, Inc. ("Isis"), for about fourteen years. Isis, the assignee of the above-identified patent application, specializes in oligonucleotide technology and uses the latest in bioinformatics programs to identify sites on selected genes for oligonucleotide screening. I am presently the Executive Director of antisense lead identification at Isis and am responsible for several projects. I lead a project utilizing antisense oligonucleotides for functional genomics of novel targets, including the use of computational genomics to characterize target RNAs and their variants, rapid throughput screening to identify active antisense oligonucleotides for novel targets, and Q-RT-PCR and microarrays for expression analysis. I also lead a project for determining microRNA function in mammals, including the use of computational identification of microRNAs and microRNA targets and the use of functional genomics to characterize microRNA biology and identify therapeutic applications of modulation